Greenberg P D, Cheever M, Fefer A
J Immunol. 1979 Aug;123(2):515-22.
Mice with advanced disseminated syngeneic tumor can be successfully treated with a combination of chemotherapy and adoptively transferred syngeneic immune cells. We have previously demonstrated that in vivo primed cells secondarily sensitized in vitro became more effective in tumor therapy, whereas primed cells cultured for 5 days without tumor stimulation became less effective than an equal number of uncultured fresh primed cells. Therefore, we examined stimulated and unstimulated cultures of tumor-primed cells for the presence of culture-induced suppressor cells, and determined whether in vivo tumor therapy with immune cells could be inhibited by concurrent inoculation of immune effector cells and cultured normal spleen cells, which contain culture-induced suppressor cells but are devoid of additional effector cells. The in vitro primary allogeneic response was suppressed by cultured normal spleen cells, or tumor-primed spleen cells previously cultured for 5 days with or without tumor stimulation. In vitro secondary sensitization to syngeneic tumor was suppressed by normal or tumor-primed cells that had previously been cultured for 5 days without stimulation. The majority of this suppression was mediated by T cells in the cultured populations. The efficacy of fresh tumor-primed cells, as well as primed cells secondarily sensitized in vitro, in adoptive chemoimmunotherapy of advanced tumor was diminished by concurrent inoculation of cultured normal cells. The cells mediating suppression of in vivo therapy required previous in vitro culture for induction, and were radiation sensitive.
患有晚期播散性同基因肿瘤的小鼠可以通过化疗和过继转移同基因免疫细胞的联合治疗成功治愈。我们之前已经证明,在体内致敏后在体外再次致敏的细胞在肿瘤治疗中变得更有效,而在没有肿瘤刺激的情况下培养5天的致敏细胞比同等数量未培养的新鲜致敏细胞效果更差。因此,我们检查了肿瘤致敏细胞的刺激培养物和未刺激培养物中是否存在培养诱导的抑制细胞,并确定用免疫细胞进行的体内肿瘤治疗是否会被同时接种免疫效应细胞和含有培养诱导抑制细胞但没有额外效应细胞的培养正常脾细胞所抑制。体外原发性同种异体反应被培养的正常脾细胞或先前在有或没有肿瘤刺激的情况下培养5天的肿瘤致敏脾细胞所抑制。对同基因肿瘤的体外二次致敏被先前在没有刺激的情况下培养5天的正常或肿瘤致敏细胞所抑制。这种抑制的大部分是由培养群体中的T细胞介导的。同时接种培养的正常细胞会降低新鲜肿瘤致敏细胞以及在体外再次致敏的致敏细胞在晚期肿瘤过继化学免疫治疗中的疗效。介导体内治疗抑制的细胞需要先前的体外培养来诱导,并且对辐射敏感。